23 Sep What the FDA 510(k) vs De Novo Decision Means for a Device Startup Timeline
For a medical device startup, the choice between a 510(k) clearance and a De Novo authorization is one of the most consequential regulatory decisions the company will make. It affects how long the regulatory process takes, what evidence must be generated before that process begins, how much it costs, and what market position the company occupies once authorization is achieved. Getting this decision right early — ideally before significant development spending has occurred — is among the highest-return investments available in the regulatory strategy phase. According to the FDA (U.S. Food and Drug Administration), the 510(k) and De Novo pathways serve fundamentally different regulatory purposes, and selecting the wrong one early can add significant time and cost to the path to market authorization.
Image by uh44464 on Magnific
The Fundamental Difference Between the Two Pathways
The 510(k) pathway is available to devices that can demonstrate substantial equivalence to a legally marketed predicate device. This does not require proof of safety and effectiveness through clinical trials — it requires a comparison that shows the new device has the same intended use and the same or equally safe and effective technological characteristics as the predicate. If that comparison is persuasive, the FDA clears the device without requiring independent clinical evidence.
Firms like Health Policy Associates work with device developers in the early stages of regulatory strategy to determine whether a viable predicate exists, whether the device’s characteristics are sufficiently comparable to support a 510(k) submission, and whether the FDA is likely to accept the proposed predicate or raise questions about substantial equivalence. This determination has direct timeline implications: a 510(k) that reaches the FDA with a well-supported predicate comparison and a complete technical file typically reviews faster than one that generates additional information requests.
When a De Novo Is Required
The De Novo pathway exists for devices that are novel enough that no appropriate predicate exists but that are not so high-risk that they require the full Premarket Approval process. A device that represents a new type of diagnostic, a new monitoring technology, or a new therapeutic modality without a comparable marketed device typically ends up at De Novo. Unlike 510(k), a De Novo authorization requires the FDA to make an affirmative determination that the device is safe and effective for its intended use and that special controls can be developed to provide reasonable assurance of that standard going forward. This is a more demanding standard, and the evidentiary package required reflects it. Clinical data is more often required, the FDA review is longer and more interactive, and the output is a De Novo authorization that itself becomes a predicate for subsequent similar devices.
How the Two Pathways Differ in Timeline
A standard 510(k) has a statutory review goal of ninety days from acceptance. In practice, the average total time from submission to decision has historically been longer, reflecting additional information requests that pause and restart the review clock. A well-prepared 510(k) with a clean predicate comparison and a complete technical file can be reviewed in the target window. A submission that generates multiple rounds of additional information can take a year or more. De Novo authorizations operate on a longer timeline at baseline. The FDA’s guidance on the De Novo process establishes a statutory review goal of one hundred and fifty days, but the nature of the review — which involves developing special controls and making classification decisions — means that the interactive review process often extends the timeline beyond the statutory goal.
Why Predicate Selection Is a Strategic Decision
For devices that might qualify for 510(k), predicate selection is where regulatory strategy is won or lost. A predicate that is closely comparable in intended use and technological characteristics makes the substantial equivalence argument straightforward. A predicate that requires significant argument about why differences in technology do not compromise safety or effectiveness creates risk of a Not Substantially Equivalent determination, which sends the company to De Novo or PMA. The FDA’s current thinking on specific predicate devices, the technology gaps it considers material, and the intended use language it finds adequate are not always derivable from public guidance documents alone. Regulatory experience with the specific device category informs these judgments in ways that matter to the submission strategy.
The Pre-Submission Meeting as a Decision-Making Tool
Both the 510(k) and De Novo pathways benefit from a Pre-Submission meeting with the FDA before the application is filed. For 510(k) submissions, a Pre-Submission can confirm whether the proposed predicate is acceptable and whether the performance testing data planned is sufficient. For De Novo, it can confirm the anticipated classification level, the special controls the FDA will expect, and the clinical evidence requirements. The investment in a Pre-Submission meeting is modest relative to the cost of a submission that reaches the FDA with a fundamental pathway or predicate problem. The output — written FDA feedback on the specific questions raised — is a durable reference that guides the submission strategy through development and filing.
For a broader overview of how FDA medical device regulatory pathways work and what device developers should understand about the Premarket Approval and 510(k) clearance processes, see this MedicalResearch.com overview of FDA medical device regulatory pathways — what developers need to know.
Disclaimer: The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. MedicalResearch.com and Eminent Domains Inc. do not warrant or endorse products or claims made by third party links. Always seek the advice of your physician or other qualified health provider and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on September 23, 2026 by Marie Benz MD FAAD